MedTrace Logo

A 6 Month Safety Extension Study of MBGS205

NCT02908074 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 143

Last updated 2023-05-18

Study results available
· View outcomes & findings →

Summary

Phase IIb, multicentre, double-blind, randomised, placebo-controlled parallel-group 36-week study evaluating safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism (HH)

Conditions

  • Hypogonadotropic Hypogonadism

Interventions

DRUG

BGS649

Capsules will be taken weekly for a maximum of 24 weeks

Sponsors & Collaborators

  • Mereo BioPharma

    lead INDUSTRY

Principal Investigators

  • Hugh Jones · Barnsley Hospital NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-15
Primary Completion
2018-09-08
Completion
2018-11-21

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02908074 on ClinicalTrials.gov